dizocilpine-maleate and budipine

dizocilpine-maleate has been researched along with budipine* in 1 studies

Other Studies

1 other study(ies) available for dizocilpine-maleate and budipine

ArticleYear
The antiparkinsonian drugs budipine and biperiden are use-dependent (uncompetitive) NMDA receptor antagonists.
    European journal of pharmacology, 1994, Oct-24, Volume: 264, Issue:2

    N-Methyl-D-aspartate- (NMDA-) evoked [3H]acetylcholine release in rabbit caudate nucleus slices was inhibited by the antiparkinsonian drugs budipine (1-tert-butyl-4,4-diphenylpiperidine) and biperiden (1-bicyclo[2.2.1.]hept-5-en-2-yl-1-phenyl-3-piperidino propanol) yielding functional Ki values of 4.6 and 8.8 microM. In contrast to the competitive antagonist 2-amino-5-phosphonopentaonate, budipine and biperidene significantly reduced both the apparent KD and the Emax value of NMDA. Moreover, they displaced [3H]MK-801 specifically bound to membranes of the same tissue, although with low affinity (IC50: 38 and 92 microM). It is concluded that budipine and biperiden are use-dependent (uncompetitive) antagonists at the NMDA receptor, binding to the receptor-linked ion channel, but probably not to the MK-801 binding site. NMDA antagonism may contribute to the antiparkinsonian effects of budipine.

    Topics: Acetylcholine; Animals; Antiparkinson Agents; Binding, Competitive; Biperiden; Caudate Nucleus; Dizocilpine Maleate; In Vitro Techniques; Piperidines; Rabbits; Receptors, N-Methyl-D-Aspartate; Software

1994